Prime Medicine Files Q1 2025 10-Q
Ticker: PRME · Form: 10-Q · Filed: May 8, 2025 · CIK: 1894562
| Field | Detail |
|---|---|
| Company | Prime Medicine, Inc. (PRME) |
| Form Type | 10-Q |
| Filed Date | May 8, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biotech
Related Tickers: PRME
TL;DR
PRME Q1 2025 10-Q filed. Financials out.
AI Summary
Prime Medicine, Inc. filed its 10-Q for the period ending March 31, 2025. The company, focused on biological products, reported its financial status for the first quarter of 2025. Key financial data and business operations for the period are detailed in this filing.
Why It Matters
This filing provides investors and stakeholders with the latest financial performance and operational updates for Prime Medicine, Inc. during the first quarter of 2025.
Risk Assessment
Risk Level: low — This is a standard quarterly financial filing with no immediate red flags.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the financial quarter covered by the report.)
- 2025-01-01 — Reporting Period Start Date (Indicates the start of the financial quarter covered by the report.)
- 2024-12-31 — Prior Year End Date (Provides a point of comparison for financial data.)
Key Players & Entities
- Prime Medicine, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- 0001894562 (company) — Central Index Key for Prime Medicine, Inc.
- 60 FIRST ST. CAMBRIDGE MA 02141 (address) — Business and mailing address for Prime Medicine, Inc.
FAQ
What is the total revenue for Prime Medicine, Inc. for the quarter ended March 31, 2025?
The provided text does not contain specific revenue figures for the quarter ended March 31, 2025.
What was the net income or loss for Prime Medicine, Inc. in Q1 2025?
Specific net income or loss figures for the quarter ended March 31, 2025, are not detailed in this excerpt.
What are the company's total assets as of March 31, 2025?
The filing excerpt does not list the total assets as of March 31, 2025.
What is the company's cash and cash equivalents balance at the end of Q1 2025?
The provided text does not specify the cash and cash equivalents balance for March 31, 2025.
What is the primary business of Prime Medicine, Inc. according to the filing?
Prime Medicine, Inc. is primarily involved in Biological Products (No Diagnostic Substances), as indicated by its SIC code [2836].
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding Prime Medicine, Inc. (PRME).